(ALNY) Alnylam Pharmaceuticals - Overview
Stock: RNAi Therapeutics, Onpattro, Amvuttra, Givlaari, Oxlumo
| Risk 5d forecast | |
|---|---|
| Volatility | 40.4% |
| Relative Tail Risk | -15.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.90 |
| Alpha | 19.59 |
| Character TTM | |
|---|---|
| Beta | 1.016 |
| Beta Downside | 1.175 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.20% |
| CAGR/Max DD | 0.49 |
EPS (Earnings per Share)
Revenue
Risks
P/E ratio: 142.8841
Description: ALNY Alnylam Pharmaceuticals March 01, 2026
Alnylam Pharmaceuticals (NASDAQ: ALNY) is a Cambridge-based biotech that pioneers RNA interference (RNAi) therapeutics, developing, manufacturing and commercializing medicines for rare and chronic diseases across the U.S., Europe and other markets.
Its approved portfolio includes ONPATTRO (hATTR amyloidosis), AMVUTTRA (ATTR amyloidosis), Leqvio (hypercholesterolemia), Qfitlia (hemophilia A/B), GIVLAARI (acute hepatic porphyria) and OXLUMO (primary hyperoxaluria type 1). In Q4 2025 the company reported $1.2 billion in total revenue, driven primarily by strong growth in Leqvio and ONPATTRO sales, while maintaining a cash balance of $2.5 billion that extends its runway into 2027.
Alnylam’s late-stage pipeline features several Phase 3 candidates: Nucresiran for ATTR amyloidosis, Zilebesiran for hypertension, and Cemdisiran targeting myasthenia gravis and geographic atrophy. Interim data for Zilebesiran are expected in H2 2025, and the company anticipates filing an NDA for Nucresiran by early 2026.
Beyond its own R&D, Alnylam leverages strategic alliances with Regeneron, Roche, Sanofi, Novartis and others, generating over $200 million in upfront and milestone payments in 2024. R&D spending remains high at $800 million for FY 2024, reflecting the capital-intensive nature of RNAi development and the broader biotech sector’s shift toward gene-silencing platforms.
For a deeper dive into ALNY’s valuation dynamics, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 313.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 10.38 > 1.0 |
| NWC/Revenue: 69.58% < 20% (prev 93.81%; Δ -24.22% < -1%) |
| CFO/TA 0.11 > 3% & CFO 524.1m > Net Income 313.7m |
| Net Debt (-378.9m) to EBITDA (472.7m): -0.80 < 3 |
| Current Ratio: 2.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.3m) vs 12m ago 5.98% < -2% |
| Gross Margin: 81.72% > 18% (prev 0.86%; Δ 8086 % > 0.5%) |
| Asset Turnover: 80.68% > 50% (prev 53.02%; Δ 27.66% > 0%) |
| Interest Coverage Ratio: 1.65 > 6 (EBITDA TTM 472.7m / Interest Expense TTM 252.6m) |
Altman Z'' -2.07
| A: 0.52 (Total Current Assets 4.05b - Total Current Liabilities 1.47b) / Total Assets 4.97b |
| B: -1.35 (Retained Earnings -6.70b / Total Assets 4.97b) |
| C: 0.09 (EBIT TTM 417.0m / Avg Total Assets 4.60b) |
| D: -1.61 (Book Value of Equity -6.72b / Total Liabilities 4.18b) |
| Altman-Z'' Score: -2.07 = D |
Beneish M -2.60
| DSRI: 1.16 (Receivables 777.6m/405.3m, Revenue 3.71b/2.25b) |
| GMI: 1.05 (GM 81.72% / 85.62%) |
| AQI: 0.71 (AQ_t 0.04 / AQ_t-1 0.06) |
| SGI: 1.65 (Revenue 3.71b / 2.25b) |
| TATA: -0.04 (NI 313.7m - CFO 524.1m) / TA 4.97b) |
| Beneish M-Score: -2.60 (Cap -4..+1) = A |
What is the price of ALNY shares?
Over the past week, the price has changed by +1.08%, over one month by -1.83%, over three months by -26.76% and over the past year by +36.71%.
Is ALNY a buy, sell or hold?
- StrongBuy: 12
- Buy: 12
- Hold: 7
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the ALNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 457 | 37.3% |
| Analysts Target Price | 457 | 37.3% |
ALNY Fundamental Data Overview March 01, 2026
P/E Forward = 36.2319
P/S = 11.8884
P/B = 55.6658
P/EG = -0.49
Revenue TTM = 3.71b USD
EBIT TTM = 417.0m USD
EBITDA TTM = 472.7m USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 45.5m USD (from shortTermDebt, last quarter)
Debt = 1.28b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -378.9m USD (from netDebt column, last quarter)
Enterprise Value = 42.52b USD (44.15b + Debt 1.28b - CCE 2.91b)
Interest Coverage Ratio = 1.65 (Ebit TTM 417.0m / Interest Expense TTM 252.6m)
EV/FCF = 91.37x (Enterprise Value 42.52b / FCF TTM 465.4m)
FCF Yield = 1.09% (FCF TTM 465.4m / Enterprise Value 42.52b)
FCF Margin = 12.53% (FCF TTM 465.4m / Revenue TTM 3.71b)
Net Margin = 8.45% (Net Income TTM 313.7m / Revenue TTM 3.71b)
Gross Margin = 81.72% ((Revenue TTM 3.71b - Cost of Revenue TTM 678.9m) / Revenue TTM)
Gross Margin QoQ = 75.60% (prev 84.21%)
Tobins Q-Ratio = 8.56 (Enterprise Value 42.52b / Total Assets 4.97b)
Interest Expense / Debt = 10.12% (Interest Expense 129.3m / Debt 1.28b)
Taxrate = 2.91% (9.40m / 323.2m)
NOPAT = 404.9m (EBIT 417.0m * (1 - 2.91%))
Current Ratio = 2.76 (Total Current Assets 4.05b / Total Current Liabilities 1.47b)
Debt / Equity = 1.62 (Debt 1.28b / totalStockholderEquity, last quarter 789.2m)
Debt / EBITDA = -0.80 (Net Debt -378.9m / EBITDA 472.7m)
Debt / FCF = -0.81 (Net Debt -378.9m / FCF TTM 465.4m)
Total Stockholder Equity = 347.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.82% (Net Income 313.7m / Total Assets 4.97b)
RoE = 90.35% (Net Income TTM 313.7m / Total Stockholder Equity 347.3m)
RoCE = 30.78% (EBIT 417.0m / Capital Employed (Equity 347.3m + L.T.Debt 1.01b))
RoIC = 29.50% (NOPAT 404.9m / Invested Capital 1.37b)
WACC = 9.66% (E(44.15b)/V(45.43b) * Re(9.66%) + D(1.28b)/V(45.43b) * Rd(10.12%) * (1-Tc(0.03)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.92%
[DCF] Terminal Value 63.09% ; FCFF base≈465.4m ; Y1≈305.5m ; Y5≈139.4m
[DCF] Fair Price = 18.83 (EV 2.12b - Net Debt -378.9m = Equity 2.50b / Shares 132.6m; r=9.66% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 78.40 | EPS CAGR: 53.70% | SUE: 0.02 | # QB: 0
Revenue Correlation: 92.33 | Revenue CAGR: 54.77% | SUE: -0.55 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.18 | Chg7d=-0.450 | Chg30d=-0.606 | Revisions Net=-3 | Analysts=10
EPS current Year (2026-12-31): EPS=9.56 | Chg7d=-0.140 | Chg30d=-1.677 | Revisions Net=-4 | Growth EPS=+88.2% | Growth Revenue=+50.3%
EPS next Year (2027-12-31): EPS=14.54 | Chg7d=-1.377 | Chg30d=-3.310 | Revisions Net=-5 | Growth EPS=+52.1% | Growth Revenue=+30.5%
[Analyst] Revisions Ratio: -0.43 (2 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 9.0% (Discount Rate 9.7% - Earnings Yield 0.7%)
[Growth] Growth Spread = +62.9% (Analyst 71.9% - Implied 9.0%)